Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025European Heart Journal - Quality of Care and Clinical OutcomesOpen Access

Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: a win ratio analysis of the NOAH-AFNET 6 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNina BecherElectrophysiologyGKGina KöllnerUniversität HamburgEBEmanuele BertagliaElectrophysiology

Discussion

Loading...

Member takes

Overview

Win ratio analysis of the NOAH-AFNET 6 trial reveals no advantage of anticoagulation in stroke risk reduction for patients with device-detected atrial fibrillation.

Key Points

  • The win ratio showed no significant advantage of edoxaban over no anticoagulation in preventing adverse events.
  • From 2534 participants, the win ratio comparing edoxaban to no anticoagulation was 0.87, suggesting no clear benefit.
  • Death and major bleeding were the most common outcomes, with a high percentage of undecided comparisons at 84.9%.
  • This analysis challenges the perceived benefits of anticoagulation therapy in patients with device-detected atrial fibrillation.

Cite This Study

Becher et al. (2025) studied this question.

synapsesocial.com/papers/68bb4d206d6d5674bcd0101bhttps://doi.org/10.1093/ehjqcco/qcaf087
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Win or tie? Rethinking anticoagulation in device-detected AF2025
  2. 2Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials2024 · 37 citations
  3. 3Improving Patient Outcomes in Preventing Atrial Fibrillation-related Stroke with Non-Vitamin K Antagonist Oral Anticoagulants2016
  4. 4Risk-benefit profile of edoxaban and warfarin in patients with atrial fibrillation: a comprehensive systematic review and meta-analysis of randomized trials2025
  5. 5Edoxaban for atrial high-rate episodes: more harm than good?2023